COMMUNICATION
News & Press Release
Total 122
-
102Neurobiogen, New Drug Candidate 'KDS2010' Dementia and Obesity Phase 2a IND Approval.
DATE : 2024-09-04
VIEW : 2354
-
101Neurobiogen, enters phase 2 clinical trial for Alzheimer's drug candidate.
DATE : 2024-09-02
VIEW : 2271
-
100Neurobiogen, "Succeeded in Phase 1 of Obesity and Dementia Treatment..."Discussion on Global Big Pha
DATE : 2024-07-22
VIEW : 2241
-
99"Wigobi there"...BioVenture Speeds Research on Native Obesity Drugs.
DATE : 2024-03-26
VIEW : 2411
-
98Kim Sang-wook, CEO of Neurobiogen, said, "We will promote the transfer of technology and treatment f
DATE : 2024-03-20
VIEW : 2504
-
97Neurobiogen "Phase 1 successful treatment for obesity and dementia...Application for Phase 2 of Q2".
DATE : 2024-03-20
VIEW : 2502
-
96Neurobiogen, obesity treatment..."It's more effective and safer" than the mainstream GLP-1.
DATE : 2024-03-20
VIEW : 2672
-
95Neurobiogen Succeeds in Phase 1 Clinical Trials for Dementia and Obesity Drugs..."Nothing is wrong w
DATE : 2024-03-20
VIEW : 2527
-
94Neurobiogen "Succeeds in Phase 1 Clinical Trials for Native Obesity Drugs..."Preparing for the 2nd G
DATE : 2024-03-20
VIEW : 2477
-
93Neurobiogen "Innovative Dementia and Obesity Treatment Phase 1 Successful..."Promoting joint develop
DATE : 2024-03-20
VIEW : 2501
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com
FAMILY SITE
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved